Claims for Patent: 6,355,422

Summary for Patent: 6,355,422

Title:	Single tube PCR assay for detection of chromosomal mutations: application to the inversion hotspot in the factor VIII gene including optional use of subcycling PCR
Abstract:	Methods are presented for determining the presence of an inversion in the factor VIII gene which cause hemophilia A. The methods encompass long distance, multiplex PCR (including overlapping PCR). The use of deaza-dGTP, high levels of DNA polymerases and high levels of DMSO aid in successfully performing the PCR. The use of a novel technique called subcycling PCR can also be applied as part of the methods. The technique allows for the determination of whether a person is homozygous or hemizygous for the inversion and has hemophilia A or whether a person is heterozygous for the inversion and is a carrier. The technique of long distance, multiplex PCR including use of deaza-dGTP, high levels of DNA polymerases and high levels of DMSO are applicable to the determination of the presence of other gross chromosomal aberrations such as deletions/inversions, translocations and inversions. The use of subcycling PCR can achieve efficient and more even amplification than normal two or three temperature PCR and is applicable to long distance, multiplex PCR.
Inventor(s):	Liu; Qiang (Arcadia, CA), Sommer; Steve S. (Duarte, CA)
Assignee:	City of Hope (Duarte, CA)
Application Number:	09/200,934
Patent Claims:	1. A method for screening for the presence of hemophilia A in a male wherein said method comprises performing long distance polymerase chain reaction (PCR) on a sample from said male using 2 primers, wherein said primers are specific for amplifying a region of an X chromosome comprising intron 22 of a factor VIII gene (Int22h1), wherein said method is performed under conditions which produce a PCR product when performed on a sample from a person who does not have hemophilia A, wherein the absence of a PCR product indicates the presence of hemophilia A in said male. 2. The method of claim 1 wherein one of said primers comprises SEQ ID NO:8 and another of said primers comprises SEQ ID NO:9. 3. A method for determining the presence of hemophilia A in a male or the presence in a female of an inversion comprising intron 22 of a factor VIII gene wherein said inversion results from a homologous recombination between Int22h1 and Int22h2 or Int22h3 and wherein said inversion results in hemophilia A when a person is hemizygous or homozygous for said inversion, wherein said method comprises performing long distance polymerase chain reaction on a sample from said male or said female using 2 primers, wherein a) a first primer is specific for a region upstream of Int22h1 and a second primer is specific for a region downstream of both Int22h2 and Int22h3 or b) a first primer is specific for a region upstream of both Int22h2 and Int22h3 and a second primer is specific for a region downstream of Int22h1, wherein the presence of a PCR product is indicative of hemophilia A in said male and is indicative of said female being a carrier of said inversion. 4. The method of claim 3 wherein said primers are selected from primers comprising a) SEQ ID NO:8 and SEQ ID NO:11, b) SEQ ID NO:8 and bases 1-36 of SEQ ID NO:11, or c) SEQ ID NO:10 and SEQ ID NO:9. 5. A method for screening for the presence of hemophilia A in a male or the absence of an inversion in either a male or the presence of said inversion in a female, wherein said inversion results from a homologous recombination between Int22h1 and Int22h2 or Int22h3 and wherein said inversion causes hemophilia A when present in a male, wherein said method comprises performing long distance, multiplex PCR on a sample from said male or from said female using 3 primers wherein a first primer is specific for an upstream region of Int22h1, a second primer is specific for a downstream region of Int22h1, and a third primer is specific for either an upstream or a downstream region of both Int22h2 and Int22h3, wherein amplification using said first primer and said second primer yields a PCR product of a first size and wherein amplification using said third primer and one of said second primer and said third primer yields a PCR product of a second size, wherein the presence of a PCR product of said first size is indicative that said male does not carry said inversion and wherein the presence of a PCR product of said second size is indicative that said male has hemophilia A or that said female is a carrier of said inversion. 6. The method of claim 5 wherein said first primer comprises SEQ ID NO:8, b) said second primer comprises SEQ ID NO:9 and c) said third primer is selected from the group consisting of a primer comprising SEQ ID NO:10, a primer comprising SEQ ID NO:11 and a primer comprising bases 1-36 of SEQ ID NO:11. 7. A method for screening for the presence of hemophilia A in a male or the absence of an inversion in a male or the presence of said inversion in a female, wherein said inversion results from a homologous recombination between Int22h1 and Int22h2 or Int22h3 and wherein said inversion causes hemophilia A when present in a male, wherein said method comprises performing long distance, multiplex PCR on a sample from said male or from said female using 3 primers wherein a first primer is specific for both an upstream region of Int22h2 and an upstream region of Int22h3, a second primer is specific for both a downstream region of Int22h2 and a downstream region of Int22h3, and a third primer is specific for either an upstream or a downstream region of Int22h1, wherein amplification using said first primer and said second primer yields a PCR product of a first size and wherein amplification using said third primer and one of said first primer and said second primer yields a PCR product of a second size, wherein the presence of a PCR product of said second size in a sample from said male is indicative of the presence of hemophilia A in said male, the absence of a PCR product of said second size in a sample from said male is indicative of the absence of said inversion in said male, the presence of a PCR product of said second size in a sample from said female is indicative that said female is a carrier of said inversion, and the absence of a PCR product of said second size in a sample from said female is indicative that said female is not a carrier of said inversion. 8. The method of claim 7 wherein said first primer comprises SEQ ID NO:10, b) said second primer comprises SEQ ID NO:11 or bases 1-36 of SEQ ID NO:11, and c) said third primer comprises SEQ ID NO:8 or SEQ ID NO:9. 9. A method for screening for the presence of hemophilia A in a male or the absence of an inversion in a male, wherein said inversion results from a homologous recombination between Int22h1 and Int22h2 or Int22h3 and wherein said inversion causes hemophilia A when present in a male, or to determine whether a female is a carrier of said inversion, wherein said method comprises performing long distance, multiplex PCR on a sample from said male or from said female using 4 or more primers wherein a first primer is specific for an upstream region of Int22h1, a second primer is specific for a downstream region of Int22h1, a third primer is specific for an upstream region of both Int22h2 and Int22h3, and a fourth primer is specific for a downstream region of both Int22h2 and Int22h3, wherein a PCR amplification product using said first primer and said second primer is a first size, a PCR amplification product using said third primer and said fourth primer is a second size, a PCR amplification product using said first primer and said fourth primer is a third size and a PCR amplification product using said second primer and said third primer is a fourth size, wherein said first size and said second size may be equal to each other and wherein said third size and said fourth size may be equal to each other, wherein the presence of PCR amplification products of said first size and said second size in a sample from a male indicates the absence of said inversion in said male, the presence of PCR amplification products of said second size, said third size and said fourth size in a sample from a male indicates the presence of hemophilia A in said male, the presence of PCR amplification products of said first size and said second size and the absence of PCR amplification products of said third size and said fourth size in a sample from a female indicates the absence of said inversion in said female, and the presence of PCR amplification products of said first size, said second size, said third size and said fourth size from a sample from said female indicates that said female is a carrier of said inversion. 10. The method of claim 9 wherein said first primer comprises SEQ ID NO:8, b) said second primer comprises SEQ ID NO:9, c) said third primer comprises SEQ ID NO:10, and d) said fourth primer comprises SEQ ID NO:11 or bases 1-36 of SEQ ID NO:11. 11. The method of claim 1 wherein said PCR comprises any combination of one, two or three of the following: i) DMSO at a concentration of at least 6%; ii) DNA polymerase at a concentration of at least 0.05 units per .mu.L; and iii) a concentration of deaza-dGTP and a concentration of dGTP wherein said concentration of deaza-dGTP is greater than or equal to 33% of said concentration of dGTP. 12. The method of claim 3 wherein said PCR comprises any combination of one, two or three of the following: i) DMSO at a concentration of at least 6%; ii) DNA polymerase at a concentration of at least 0.05 units per .mu.L; and iii) a concentration of deaza-dGTP and a concentration of dGTP wherein said concentration of deaza-dGTP is greater than or equal to 33% of said concentration of dGTP. 13. The method of claim 5 wherein said PCR comprises any combination of one, two or three of the following: i) DMSO at a concentration of at least 6%; ii) DNA polymerase at a concentration of at least 0.05 units per .mu.L; and iii) a concentration of deaza-dGTP and a concentration of dGTP wherein said concentration of deaza-dGTP is greater than or equal to 33% of said concentration of dGTP. 14. The method of claim 7 wherein said PCR comprises any combination of one, two or three of the following: i) DMSO at a concentration of at least 6%; ii) DNA polymerase at a concentration of at least 0.05 units per .mu.L; and iii) a concentration of deaza-dGTP and a concentration of dGTP wherein said concentration of deaza-dGTP is greater than or equal to 33% of said concentration of dGTP. 15. The method of claim 9 wherein said PCR comprises any combination of one, two or three of the following: i) DMSO at a concentration of at least 6%; ii) DNA polymerase at a concentration of at least 0.05 units per .mu.L; and iii) a concentration of deaza-dGTP and a concentration of dGTP wherein said concentration of deaza-dGTP is greater than or equal to 33% of said concentration of dGTP. 16. The method of claim 1 wherein i) said PCR comprises two temperatures, ii) said PCR comprises three temperatures, or iii) said PCR comprises subcycling PCR. 17. The method of claim 3 wherein i) said PCR comprises two temperatures, ii) said PCR comprises three temperatures, or iii) said PCR comprises subcycling PCR. 18. The method of claim 5 wherein i) said PCR comprises two temperatures, ii) said PCR comprises three temperatures, or iii) said PCR comprises subcycling PCR. 19. The method of claim 7 wherein i) said PCR comprises two temperatures, ii) said PCR comprises three temperatures, or iii) said PCR comprises subcycling PCR. 20. The method of claim 9 wherein i) said PCR comprises two temperatures, ii) said PCR comprises three temperatures, or iii) said PCR comprises subcycling PCR. 21. The method of claim 5 wherein said PCR is performed in a single reaction vessel. 22. The method of claim 7 wherein said PCR is performed in a single reaction vessel. 23. The method of claim 9 wherein said PCR is performed in a single reaction vessel. 24. A nucleic acid comprising at least 13 consecutive bases of a DNA sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11 and bases 1-36 of SEQ ID NO:11. 25. A nucleic acid of claim 24 wherein said DNA sequence is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:5. 26. A nucleic acid of claim 24 wherein said DNA sequence is selected from the group consisting of SEQ ID NO:3, SEQ ID NO:6 and SEQ ID NO:7. 27. A nucleic acid of claim 26 wherein said DNA sequence is selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11 and bases 1-36 of SEQ ID NO:11. 28. A nucleic acid consisting of a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11 and bases 1-36 of SEQ ID NO:11.

Details for Patent 6,355,422

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2018-06-24
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2018-06-24
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2018-06-24